Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Optimising methotrexate and PLGA coated intraocular lenses in PCO prophylaxis

Poster Details

First Author: S.Kassumeh GERMANY

Co Author(s):    A. von Studnitz   A. Hillenmayer   C. Priglinger   S. Priglinger   A. Ohlmann   C. Wertheimer     

Abstract Details


The intraocular lens as a drug delivery device is a promising method in prophylaxis of posterior capsular opacification (PCO). Among many pharmaceutical substances, methotrexate has been identified as the most effective whilst the least toxic. Polylactic-co-glycolic acid (PLGA) is a biodegradable copolymer used in drug releasing devices as a slow degradable carrier. The following is to determine a useful combination of drug concentration, PLGA composition and solvent for optimized drug delivery.


Cell- and molecular biology laboratory, Department of Ophthalmology, Ludwig-Maximilian-University, Munich, Germany


Different solvents were tested on their compatibility with hydrophobic intraocular lens and the dissolving properties of PLGA and methotrexate. Intraocular lenses were loaded with increasing concentrations of drug. Release kinetics of the IOL were measured in an anterior segment aqueous humor flow model.


Higher solubility of PLGA and methotrexate in solvents seems to correlate with damage to the hydrophobic IOL material. Currently isopropanol appears to be the most suitable solvent as it does not damage the intraocular lens while being able to dissolve a significant amount of PLGA, when compared to other anorganic or organic solvents. In the release kinetic measurements, tested combinations show an initial concentration peak followed by a subsequent release of methotrexate in therapeutic dosage for at least 14 days.


The combination of isopropanol, methotrexate, PLGA and the hydrophobic intraocular lens acrylate allows the development of a biocompatible medical device with long-term drug release. Regarding in-vivo impact, animal studies are needed.

Financial Disclosure:


Back to Poster listing